| Business Summary | | BioLabs,
Inc.,
doing
business
as
Genesis
Bioventures
(GBI),
utilizes
the
scientific
and
business
management
expertise
of
its
management
team
to
evaluate
and
select
promising
early
stage
biotechnology
companies
for
investment.
As
a
financial
facilitator
in
the
biotech
sector,
the
Company
is
actively
involved
with
its
portfolio
companies
and
serves
as
a
strategic
advisor
in
key
aspects
of
science,
product
commercialization,
business
issues
and
financial
development
by
providing
management
expertise
aimed
at
transforming
promising
medical
technology
into
successful
commercial
products.
These
portfolio
companies
typically
have
products
in
the
earlier
stages
of
development
prior
to
initiation
of
clinical
trials.
As
of
December
31,
2000
GBI
has
investments
in
three
portfolio
companies,
with
two
in
the
field
of
oncology
and
one
in
neurology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GBI
is
engaged
in
the
business
of
identifying
promising
biotechnology
companies,
acquiring
an
equity
interest
in
these
groups
and
providing
management
services
to
assist
with
their
corporate
development.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
totalled
$5.7
million,
up
from
$1.6
million.
Results
reflects
increased
salary
and
benefit
expenses
and
increased
management
and
consulting
fees. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| E. Greg McCartney, 49 Chairman,
Pres, CEO | $91K | T.J. Louis McKinney, 66 CFO,
Director | -- | Lawrence Pasemko, 64 Exec.
VP, Director | 91K | Ian Woods, M.D., Ph.D., 56 VP,
Science and Technology, | 61K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|